Otsuka's PTSD therapy draws efficacy concerns at FDA ahead of AdCom meeting
Source: SeekingAlpha
2025-07-16 14:25:11 ET
More on Otsuka Holdings, H. Lundbeck A/S
- Lundbeck Delivering On The Financials, But Needs Some Positive Clinical Drivers
- Vera plunges as Otsuka outperforms with IgA nephropathy therapy
- Seeking Alpha’s Quant Rating on Otsuka Holdings
- Historical earnings data for Otsuka Holdings
- Dividend scorecard for Otsuka Holdings
Read the full article on Seeking Alpha
For further details see:
Otsuka’s PTSD therapy draws efficacy concerns at FDA ahead of AdCom meeting
Viatris Inc.
NASDAQ: VTRS
VTRS Trading
0.11% G/L:
$13.75 Last:
2,149,017 Volume:
$13.89 Open:
VTRS Latest News
February 27, 2026 03:57:23 pm
Bastion Bets on Government Spending with $8 Million New Stake in Parsons
February 26, 2026 06:55:00 am
Viatris Maintains Dividend Policy for 2026 and Announces Quarterly Dividend
VTRS Stock Data
$18,451,353,349
1,140,252,173
N/A
503
N/A
Pharmaceuticals
Healthcare
US
Canonsburg
